COMPARING MOMELOTINIB VS DOSE-ADJUSTED RUXOLITINIB FOR TREATMENT-NAÏVE, CYTOPENIC MYELOFIBROSIS
Your site is identified as a SWOG member, and we invite your participation in the SWOG Clinical Trials Partnerships (CTP).
SWOG CTP is an independent, limited liability, non-profit corporation with its own leadership, processes, and funding agreements. But the missions of SWOG and SWOG CTP are the same - to significantly improve lives through cancer clinical trials and translational research. SWOG's governing bodies direct our SWOG CTP research.
The purpose of this study is to compare momelotinib and ruxolitinib as treatments for myelofibrosis with low blood cell counts. Both drugs are approved by the FDA to treat myelofibrosis. The study asks which drug does a better job at shrinking the spleen.
The following questionnaire aims to collect essential information about potential clinical trial sites to evaluate their suitability for the upcoming study. Please complete the summary by providing accurate and detailed responses to each section.
Your input will greatly assist in assessing the feasibility of these sites and ensuring the successful execution of the study. Thank you for your participation in this site survey.
The following questionnaire aims to collect essential information about potential clinical trial sites to evaluate their suitability for the upcoming study. Please complete the summary by providing accurate and detailed responses to each section.
Your input will greatly assist in assessing the feasibility of these sites and ensuring the successful execution of the study. Thank you for your participation in this site survey.